Cargando…
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the r...
Autores principales: | Haley, Connie A., Macias, Patricia, Jasuja, Supriya, Jones, Betsy A., Rowlinson, Marie-Claire, Jaimon, Roshni, Onderko, Pennelyn, Darnall, Elaine, Gomez, Maria E., Peloquin, Charles, Ashkin, David, Goswami, Neela D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774582/ https://www.ncbi.nlm.nih.gov/pubmed/33227229 http://dx.doi.org/10.3201/eid2701.203766 |
Ejemplares similares
-
1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021) -
2354. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for rifampin-resistant or treatment-intolerant TB disease
por: Haley, Connie A, et al.
Publicado: (2022) -
Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring
por: Ashkin, Alex, et al.
Publicado: (2023) -
Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014
por: Heysell, Scott K., et al.
Publicado: (2015) -
Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
por: McDowell, Ashley, et al.
Publicado: (2020)